February 26, 2018 / 12:22 PM / in 4 months

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

Feb 26 (Reuters) - Merrimack Pharmaceuticals Inc:

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

* MERRIMACK PHARMA SAYS SHERLOC PHASE 2 STUDY ASSESSING MM-121 WITH DOCETAXEL VERSUS DOCETAXEL ALONE IS EXPECTED TO DELIVER TOP-LINE DATA IN H2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below